ClinicalTrials.gg
Status unknownNCT04919733Updated May 26, 2022

Fluoroscopy Reduction or Elimination in CIED Implants

An interventional study of Fluoroscopy reduction in Bradycardia, Tachycardia, Ventricular and Heart Failure, sponsored by Université de Sherbrooke. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Jan 2020, registered May 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

CIED implants require different amounts of fluoroscopy; using 3-D mapping systems, these times could be reduced to near zero fluoroscopy. The investigators aim to describe to what extent fluoroscopy times are reduced on a routine basis on CIED implants

Read the detailed description

Patients with either brady arrhythmias, tachyarrhythmias, heart failure or primary prevention of sudden death receive a cardiac implantable electronic device (CIED) as a standard of care based on guideline indications. All implants require X-ray equipment to visualize the advancement and positioning of leads in different heart chambers. To date only anecdotical cases have been reported in the literature, of implants without fluoroscopy, mostly pregnant patients with a CIED indication that could not wait for implant after delivery or some rare situations where ultrasound was used to guide the leads trough the heart.

There are two reported experiences using St-Jude Abbot 3-D NavX system; where 35 (ICD and pacemakers) and 15 (VVI pacemakers only) CIED patients were respectively approached with times reported to right ventricular lead implant of 18 +/- 22 minutes and atrial lead implant of 16 +/- 9 minutes, in 89% of cases a final fluoroscopy shot was deemed necessary (in 16% of patients it was needed to correct final position); in the second report with VVI only pacemakers, the implant of a single lead was 10.1 +/- 5.4 minutes, and the total procedure duration was 59.3 +/- 15.16 minutes -one patient needed fluoroscopy-, this last cohort was compared to previous 15 VVI pacemaker patients implanted under fluoroscopy, with control times of 51.5 +/- 12.3 minutes6 (p=ns); both studies reported around 10 minutes needed to obtain right chamber anatomies. There is a little more experience on biventricular implants with two reports one single center and then the same Italian group with a multicenter study achieving a significant reduction in fluoroscopy times: from 16 minutes to 4 minutes (ranges from 11-26 to 0.3-10.4 minutes) compared with a historical control, and with the same success rates to left lead implants; even in experienced centers (more than 10 previous implants) the median time was 3 minutes of fluoroscopy when a St-Jude Abbot NavX system was used.

The advancement on 3-D mapping systems, allows nowadays to reduce and even eliminate the need of X-rays for most of ablation procedures, where the catheters advancement, positioning and navigation through the four heart chambers is accomplished with minimal or no irradiation to the patients and to the health care personnel.

The hypothesis is that use of standard 3-D mapping systems to achieve CIED implants is feasible, safe, and that could be accomplished in a time efficient way. This will be the first large report for all type of CIED implants and with all available 3-D mapping system utilization; the investigators will try also to define if a complete reconstructed virtual anatomy is needed of if a rough anatomy is sufficient to achieve the implant, and speed procedure times.

02

Conditions studied

  • Bradycardia
  • Tachycardia, Ventricular
  • Heart Failure

Keywords

  • CIED implant
  • Fluoroscopy reduction
03

In context

Bradycardia

313 studies on the registry are indexed under Bradycardia; 70 are open to participants now.

This study's planned enrollment of 150 is above the median of 99 across 179 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

Université de Sherbrooke is the lead sponsor of 296 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CIED implants

Exclusion criteria

Exclusion Criteria:

  • Patients with an urgent life-threatening indication requiring an urgent CIED implant.
  • Patients with known venous system abnormalities (as venous occlusion or abandoned non-accessible leads).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Non fluoroscopy CIED implant

    Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system

    Device: Fluoroscopy reduction

Interventions

  • DeviceFluoroscopy reduction

    To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED

06

What researchers measure

Primary outcomes

  1. Fluoroscopy time needed to implant a CIED while using 3-D mapping systems to reduce fluoroscopy exposure

    Fluoroscopy time while implanting a CIED

    Time frame: During implant procedure

  2. Peak skin dose of radiation exposure during CIED implant

    Radiation exposure expressed as total Cumulative Air Kerma (mGy)

    Time frame: During implant procedure

  3. Radiation exposure (kerma-area product) during CIED implant

    Total Dose Area Product (uGy-m2)

    Time frame: During implant procedure

  4. Total procedural time

    Time of the patient entering the lab, to the time the patient exits the lab

    Time frame: During implant procedure

  5. Safety issues arising because of reduction of fluoroscopy

    Complications arising while using a reduced fluoroscopy environment

    Time frame: During implant procedure

Secondary outcomes

  1. Detailed 3-D mapping needed Y/N

    Is it necessary to create a detailed anatomy to navigate leads without fluoroscopy

    Time frame: During implant procedure

  2. Current of lesion at desired implant fixation site (Y/N)

    If current of lesion is necessary to ascertain that the fixation mechanism is already deployed

    Time frame: During implant procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jan 2024, 48 months after the start.

Of 40 non-industry interventional studies with no phase under Bradycardia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 48 months is above that.

Counting every sponsor, half of 75 studies reached it within 20 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
Jun 9, 2021
StartActual
Jan 3, 2020
Primary completionEst.
Jan 3, 2024
CompletionEst.
Mar 3, 2024
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04919733
Responsible party
Sponsor
First posted
Jun 9, 2021
Start date
Jan 3, 2020
Primary completion
Jan 3, 2024 (estimated)
Completion
Mar 3, 2024 (estimated)
Last update
May 26, 2022

Study contacts

Felix AYALA PAREDES, MD, PhD
Contact
felix.ayala-paredes@usherbrooke.ca
819 346 1110 ext. 74947
Claude JEAN, RN
Contact
claude.jean.ciussse-chus@ssss.gouv.qc.ca
819 346 1110 ext. 16317
Felix AYALA PAREDES, MD, PhD
principal investigator · University of Shebrooke Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion